Laninamivir Explained

Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.[1] It is currently in Phase III clinical trials.[2] It is a long-acting neuraminidase inhibitor administered by nasal inhalation.[3]

Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US.[5] It is under clinical evaluations in other countries.[6]

Notes and References

  1. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S . CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity . Antimicrobial Agents and Chemotherapy . 53 . 1 . 186–192 . January 2009 . 18955520 . 2612152 . 10.1128/AAC.00333-08 .
  2. Hayden F . Developing new antiviral agents for influenza treatment: what does the future hold? . Clinical Infectious Diseases . 48 Suppl 1 . S1 . S3-13 . January 2009 . 19067613 . 10.1086/591851 . 48 . free .
  3. Samson M, Pizzorno A, Abed Y, Boivin G . Influenza virus resistance to neuraminidase inhibitors . Antiviral Research . 98 . 2 . 174–185 . May 2013 . 23523943 . 10.1016/j.antiviral.2013.03.014 .
  4. Web site: Aviragen Therapeutics - Home . 2013-04-12 . 2016-04-17 . https://web.archive.org/web/20160417124102/http://www.biotapharma.com/ . dead .
  5. Web site: Biota Pharmaceuticals - Home . 2013-04-12 . 2016-03-05 . https://web.archive.org/web/20160305125510/http://biotapharma.com/?page=1021001&subpage=1021019 . dead .
  6. Book: Ishjida T . Treatment Guidelines for Influenza Virus Infection: What Does the Recent Guideline State? . Fujita J . Influenza: Advances in Diagnosis and Management . Respiratory Disease Series: Diagnostic Tools and Disease Managements. . Springer . Singapore . 10.1007/978-981-15-9109-9_13 . 978-981-15-9109-9 . https://books.google.com/books?id=J0UIEAAAQBAJ&dq=Laninamivir+clinical+evaluations+in+other+countries&pg=PA132 . 2020 . 129–136 (132) . 228892521 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Laninamivir".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.